The case presented here demonstrates that a young infant can respond to less than 0.6 mL of D+ RBCs and documents the youngest patient to have developed a RBC alloantibody from a PLT transfusion. To prevent anti-D formation, we recommend administering Rh immunoglobulin to all D- pediatric patients that receive PLT transfusions from D+ donors [correction].

REFERENCE 1. Chiaroni J, Legrand D, Dettori I, Ferrera V. Analysis of ABO discrepancies occurring in 35 French hospitals. Transfusion

SUMMARYWe bave selected a buman EBV-transformed cell line from tbe involved lympb nodes of an ovarian cancer patient wbicb secretes an IgG 1 K antibody, able to recognize an antigen present on Ibe surface of ovarian cancer cells. The antigen, termed ' 14C1,' bas previously been shown by immunobistological tecbniques to be present on tbe surface of tbe malignant cells witbin tumour specimens. Western blotting analysis bas sbown Ibat tbe majority of primary ovarian cancer specimens and tbree continuous cell lines derived tberefrom express 14CI; otber tissue types were negative. Preliminary biocbemical cbaracterization bas been carried out, wbicb sbows tbat tbe 14CI antigen bas a molecular weight range of 25-32 kD and an isoelectric point from pf 6-3 to 6S. We believe that the 14C1 antigen is immunologically relevant to ovarian cancer patients and may tberefore represent a novel target for botb active and passive immunotherapy.